Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (81-90 of 231) with videos related to

Pageof 24
Sort By:
Cancer|May 23, 2012
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversyShaheenah Dawood, Asim Jamal Shaikh, Thomas A Buchholz, et al.
International Journal of Molecular Sciences|August 12, 2023
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 DomainVictor L Cruz, Virginia Souza-Egipsy, María Gion, et al.
Seminars in Oncology|August 31, 2015
Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?Gloria J Morris, Shaheenah Dawood, Javier Cortes, et al.
Nature Reviews. Disease Primers|September 25, 2019
Breast cancerNadia Harbeck, Frédérique Penault-Llorca, Javier Cortes, et al.
Heliyon|May 17, 2021
Environmental risk factors associated with respiratory diseases in children with socioeconomic disadvantageJavier Cortes-Ramirez, Juan D Wilches-Vega, Olga M Paris-Pineda, et al.
Clinical Breast Cancer|April 24, 2012
Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomesRoberto Ochoa, Ashkay Sudhindra, Monica Garcia-Buitrago, et al.
Annals of Global Health|November 9, 2022
Research and Innovation Opportunities to Improve Epidemiological Knowledge and Control of Environmentally Driven ZoonosesTatiana Proboste, Ameh James, Adam Charette-Castonguay, et al.
Breast Cancer Research and Treatment|May 19, 2022
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature reviewEdith A Perez, Chau Dang, Caleb Lee, et al.
Breast Cancer : Basic and Clinical Research|July 12, 2016
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerChris Twelves, Ahmad Awada, Javier Cortes, et al.
Annals of Surgical Oncology|July 1, 2016
Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of ResponseSebastian Diaz-Botero, Martin Espinosa-Bravo, Victor Rodrigues Gonçalves, et al.
Pageof 24

Showing results (81-90 of 231) with videos related to

Sort By:
Pageof 24
Cancer|May 23, 2012
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversyShaheenah Dawood, Asim Jamal Shaikh, Thomas A Buchholz, et al.
International Journal of Molecular Sciences|August 12, 2023
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 DomainVictor L Cruz, Virginia Souza-Egipsy, María Gion, et al.
Seminars in Oncology|August 31, 2015
Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?Gloria J Morris, Shaheenah Dawood, Javier Cortes, et al.
Nature Reviews. Disease Primers|September 25, 2019
Breast cancerNadia Harbeck, Frédérique Penault-Llorca, Javier Cortes, et al.
Heliyon|May 17, 2021
Environmental risk factors associated with respiratory diseases in children with socioeconomic disadvantageJavier Cortes-Ramirez, Juan D Wilches-Vega, Olga M Paris-Pineda, et al.
Clinical Breast Cancer|April 24, 2012
Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomesRoberto Ochoa, Ashkay Sudhindra, Monica Garcia-Buitrago, et al.
Annals of Global Health|November 9, 2022
Research and Innovation Opportunities to Improve Epidemiological Knowledge and Control of Environmentally Driven ZoonosesTatiana Proboste, Ameh James, Adam Charette-Castonguay, et al.
Breast Cancer Research and Treatment|May 19, 2022
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature reviewEdith A Perez, Chau Dang, Caleb Lee, et al.
Breast Cancer : Basic and Clinical Research|July 12, 2016
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerChris Twelves, Ahmad Awada, Javier Cortes, et al.
Annals of Surgical Oncology|July 1, 2016
Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of ResponseSebastian Diaz-Botero, Martin Espinosa-Bravo, Victor Rodrigues Gonçalves, et al.
Pageof 24